SIU-ICUD recommendations on bladder cancer: Systemic therapy for metastatic bladder cancer Journal Article


Authors: Merseburger, A. S.; Apolo, A. B.; Chowdhury, S.; Hahn, N. M.; Galsky, M. D.; Milowsky, M. I.; Petrylak, D.; Powles, T.; Quinn, D. I.; Rosenberg, J. E.; Siefker-Radtke, A.; Sonpavde, G.; Sternberg, C. N.
Article Title: SIU-ICUD recommendations on bladder cancer: Systemic therapy for metastatic bladder cancer
Abstract: The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
Keywords: bladder cancer; urothelial cancer; checkpoint inhibitors; chemotherapy immunotherapy
Journal Title: World Journal of Urology
Volume: 37
Issue: 1
ISSN: 0724-4983
Publisher: Springer  
Date Published: 2019-01-01
Start Page: 95
End Page: 105
Language: English
DOI: 10.1007/s00345-018-2486-1
PUBMED: 30238401
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric Score
MSK Authors
  1. Jonathan Eric Rosenberg
    225 Rosenberg